# | Title | Journal | Year | Citations |
---|
1 | Brain health: time matters in multiple sclerosis | Multiple Sclerosis and Related Disorders | 2016 | 280 |
2 | Is it time to target no evident disease activity (NEDA) in multiple sclerosis? | Multiple Sclerosis and Related Disorders | 2015 | 275 |
3 | Treatment of neuromyelitis optica: Review and recommendations | Multiple Sclerosis and Related Disorders | 2012 | 217 |
4 | High doses of biotin in chronic progressive multiple sclerosis: A pilot study | Multiple Sclerosis and Related Disorders | 2015 | 191 |
5 | Vitamin D and multiple sclerosis: An update | Multiple Sclerosis and Related Disorders | 2017 | 183 |
6 | Classifying PML risk with disease modifying therapies | Multiple Sclerosis and Related Disorders | 2017 | 181 |
7 | MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder | Multiple Sclerosis and Related Disorders | 2018 | 158 |
8 | The COVID-19 pandemic and the use of MS disease-modifying therapies | Multiple Sclerosis and Related Disorders | 2020 | 153 |
9 | COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? | Multiple Sclerosis and Related Disorders | 2020 | 138 |
10 | Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis | Multiple Sclerosis and Related Disorders | 2016 | 133 |
11 | Multiple sclerosis following SARS-CoV-2 infection | Multiple Sclerosis and Related Disorders | 2020 | 127 |
12 | B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran | Multiple Sclerosis and Related Disorders | 2020 | 123 |
13 | People with MS are less physically active than healthy controls but as active as those with other chronic diseases: An updated meta-analysis | Multiple Sclerosis and Related Disorders | 2017 | 118 |
14 | Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain | Multiple Sclerosis and Related Disorders | 2020 | 118 |
15 | Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial | Multiple Sclerosis and Related Disorders | 2016 | 117 |
16 | Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years | Multiple Sclerosis and Related Disorders | 2014 | 116 |
17 | The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis | Multiple Sclerosis and Related Disorders | 2018 | 113 |
18 | Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review | Multiple Sclerosis and Related Disorders | 2019 | 111 |
19 | Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients | Multiple Sclerosis and Related Disorders | 2020 | 110 |
20 | The effect of exercise training in adults with multiple sclerosis with severe mobility disability: A systematic review and future research directions | Multiple Sclerosis and Related Disorders | 2017 | 109 |
21 | Effects of MS disease-modifying therapies on responses to vaccinations: A review. | Multiple Sclerosis and Related Disorders | 2020 | 107 |
22 | Smoking and multiple sclerosis: A systematic review and meta-analysis using the Bradford Hill criteria for causation | Multiple Sclerosis and Related Disorders | 2017 | 106 |
23 | Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings | Multiple Sclerosis and Related Disorders | 2014 | 105 |
24 | Effect of intermittent vs. daily calorie restriction on changes in weight and patient-reported outcomes in people with multiple sclerosis | Multiple Sclerosis and Related Disorders | 2018 | 105 |
25 | The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most? | Multiple Sclerosis and Related Disorders | 2018 | 104 |
26 | How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms | Multiple Sclerosis and Related Disorders | 2020 | 104 |
27 | Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study | Multiple Sclerosis and Related Disorders | 2014 | 102 |
28 | Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates | Multiple Sclerosis and Related Disorders | 2014 | 102 |
29 | The multiple sclerosis gut microbiota: A systematic review | Multiple Sclerosis and Related Disorders | 2020 | 102 |
30 | Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group | Multiple Sclerosis and Related Disorders | 2018 | 101 |
31 | Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models | Multiple Sclerosis and Related Disorders | 2019 | 101 |
32 | Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis | Multiple Sclerosis and Related Disorders | 2016 | 100 |
33 | Prevalence of fatigue and its association with clinical features in progressive and non-progressive forms of Multiple Sclerosis | Multiple Sclerosis and Related Disorders | 2019 | 95 |
34 | Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis | Multiple Sclerosis and Related Disorders | 2019 | 94 |
35 | Review: Patient-reported outcomes in multiple sclerosis care | Multiple Sclerosis and Related Disorders | 2019 | 94 |
36 | Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis | Multiple Sclerosis and Related Disorders | 2019 | 94 |
37 | Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses | Multiple Sclerosis and Related Disorders | 2017 | 92 |
38 | Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers | Multiple Sclerosis and Related Disorders | 2019 | 92 |
39 | Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment | Multiple Sclerosis and Related Disorders | 2020 | 91 |
40 | Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders | Multiple Sclerosis and Related Disorders | 2017 | 89 |
41 | Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis | Multiple Sclerosis and Related Disorders | 2018 | 89 |
42 | Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database | Multiple Sclerosis and Related Disorders | 2015 | 87 |
43 | Tumefactive demyelinating lesions: A comprehensive review | Multiple Sclerosis and Related Disorders | 2017 | 87 |
44 | A case of possible atypical demyelinating event of the central nervous system following COVID-19 | Multiple Sclerosis and Related Disorders | 2020 | 87 |
45 | Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group | Multiple Sclerosis and Related Disorders | 2015 | 85 |
46 | How does cognition relate to employment in multiple sclerosis? A systematic review | Multiple Sclerosis and Related Disorders | 2018 | 85 |
47 | Effectiveness of telerehabilitation interventions in persons with multiple sclerosis: A systematic review | Multiple Sclerosis and Related Disorders | 2015 | 84 |
48 | Optimizing therapy early in multiple sclerosis: An evidence-based view | Multiple Sclerosis and Related Disorders | 2015 | 83 |
49 | Virtual reality in multiple sclerosis – A systematic review | Multiple Sclerosis and Related Disorders | 2016 | 83 |
50 | Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States | Multiple Sclerosis and Related Disorders | 2021 | 81 |